More pivotal COPD data for Almirall/Forest support filings
This article was originally published in Scrip
Almirall and Forest Laboratories have released top-line results from a second pivotal Phase III trial of its LAMA/LABA combination treatment for COPD, which failed to hit one of its co-primary endpoints.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.